FINWIRES · TerminalLIVE
FINWIRES

$ASTH

3 stories mentioning ASTHUpdated just now

Every FINWIRES story that references ASTH, newest first.

What are analysts saying about ASTH?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on ASTH?

Sectors

Sector Update: Healthcare Stocks Rise Thursday Afternoon

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index adding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4%.The iShares Biotechnology ETF (IBB) gained 1.8%.In corporate news, Novo Nordisk (NVO) and Orbis Medicines struck an up to $1.4 billion licensing deal for the private company to develop oral drugs for cardiometabolic diseases. Novo will also make a "strategic investment" in Orbis. Separately, Novo said Thursday that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended marketing authorization for Frehemgo or denecimig in the EU to treat haemophilia A, a bleeding disorder. Novo shares rose 3.5%.Nuvation Bio (NUVB) shares gained 5.7% after the company said the US Food and Drug Administration has approved its supplemental new drug application for taletrectinib to treat non-small cell lung cancer.Astrana Health (ASTH) shares fell 3.5% after short seller GlassHouse Research published a report alleging that the company's profitability depends on its management's subjective estimates.

$ASTH$NUVB$NVO
Wire

Astrana Health Shares Fall After GlassHouse Research Publishes Short-Seller Report

Astrana Health (ASTH) shares fell 2% in Thursday trading after short seller GlassHouse Research published a report alleging that the company's profitability depends on its management's subjective estimates.GlassHouse said the company's reported growth depends on a "continuous, debt-funded" acquisition pipeline, and that the growth story "nearly disappears" without acquisitions.GlassHouse criticized the company's acquisition of Prospect Health, claiming the deal "created a spring-loading setup, not a reserve overstatement already proven.""Even insiders struggled to explain the Prospect deal, and the bench is turning over," the report said.Astrana Health did not immediately respond to' request for comment.Price: $36.95, Change: $-0.75, Percent Change: -1.99%

$ASTH
Research

Oppenheimer Initiates Astrana Health at Outperform With $53 Price Target

Astrana Health (ASTH) has an average rating of buy and mean price target of $51.50, according to analysts polled by FactSet.

$ASTH

Track with the FINWIRES app suite